200 related articles for article (PubMed ID: 11121646)
21. Prospective multicenter study of bone scintigraphy in consecutive patients with newly diagnosed prostate cancer.
Zacho HD; Barsi T; Mortensen JC; Mogensen MK; Bertelsen H; Josephsen N; Petersen LJ
Clin Nucl Med; 2014 Jan; 39(1):26-31. PubMed ID: 24217537
[TBL] [Abstract][Full Text] [Related]
22. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
23. A study on staging bone scans in newly diagnosed prostate cancer.
Ayyathurai R; Mahapatra R; Rajasundaram R; Srinivasan V; Archard NP; Toussi H
Urol Int; 2006; 76(3):209-12. PubMed ID: 16601380
[TBL] [Abstract][Full Text] [Related]
24. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
25. [The indication of bone scan for patients with newly diagnosed prostate cancer].
Liu D; Wang W; Qiao LD; Zheng YP; Liu YX; Zhang GY; Chen S
Zhonghua Wai Ke Za Zhi; 2012 May; 50(5):443-5. PubMed ID: 22883953
[TBL] [Abstract][Full Text] [Related]
26. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
[TBL] [Abstract][Full Text] [Related]
27. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.
Rudoni M; Antonini G; Favro M; Baroli A; Brambilla M; Cardani G; Ciardi L; Sacchetti GM; Inglese E
Eur J Nucl Med; 1995 Mar; 22(3):207-11. PubMed ID: 7540551
[TBL] [Abstract][Full Text] [Related]
28. [Bone scintigraphy findings in patients with recently diagnosed adenocarcinoma of the prostate: relationship with prostate specific antigen levels].
Ortega A; Alonso JC; Suárez M; Domínguez P; Almoguera I; Bittini A; Gómez A; Martínez L; Herranz F; Pérez-Vázquez JM
Rev Esp Med Nucl; 2000 Oct; 19(6):409-15. PubMed ID: 11060270
[TBL] [Abstract][Full Text] [Related]
29. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
[TBL] [Abstract][Full Text] [Related]
30. Bone scan overuse in staging of prostate cancer: an analysis of a Veterans Affairs cohort.
Palvolgyi R; Daskivich TJ; Chamie K; Kwan L; Litwin MS
Urology; 2011 Jun; 77(6):1330-6. PubMed ID: 21492911
[TBL] [Abstract][Full Text] [Related]
31. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy.
Dotan ZA; Bianco FJ; Rabbani F; Eastham JA; Fearn P; Scher HI; Kelly KW; Chen HN; Schöder H; Hricak H; Scardino PT; Kattan MW
J Clin Oncol; 2005 Mar; 23(9):1962-8. PubMed ID: 15774789
[TBL] [Abstract][Full Text] [Related]
32. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
[TBL] [Abstract][Full Text] [Related]
33. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119
[TBL] [Abstract][Full Text] [Related]
34. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
35. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
36. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
[TBL] [Abstract][Full Text] [Related]
37. Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?
Lee SH; Chung MS; Park KK; Yom CD; Lee DH; Chung BH
World J Urol; 2012 Apr; 30(2):265-9. PubMed ID: 21779835
[TBL] [Abstract][Full Text] [Related]
38. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
Bruwer G; Heyns CF; Allen FJ
Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
[TBL] [Abstract][Full Text] [Related]
39. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
[TBL] [Abstract][Full Text] [Related]
40. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
Oesterling JE; Martin SK; Bergstralh EJ; Lowe FC
JAMA; 1993 Jan; 269(1):57-60. PubMed ID: 7677962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
